机构：[1]Department of Urology, Third Xiangya Hospital, Central South University,Changsha, Hunan, China[2]Department of Urology, the Second Hospital ofJilin University, Changchun, China[3]Department of Urology, SouthwestHospital, Third Military Medical University, Chongqing, China[4]Department ofUrology, Xijing Hospital, the Fourth Military Medical University, Xi’an, China[5]Department of Urology, Fudan University Shanghai Cancer Center,Shanghai, China[6]Department of Urology, Peking University Third Hospital,Beijing, China[7]Department of Urology, Shenzhen Zhongshan UrologicalHospital, Shenzhen, China深圳市康宁医院深圳医学信息中心中国医学科学院阜外医院深圳医院[8]Department of Urology, Shenzhen People’sHospital, The Second Clinical Medical College of Ji’nan University, Shenzhen,China深圳市康宁医院深圳市人民医院深圳医学信息中心[9]Department of Urology, Beijing Tongren Hospital Capital MedicalUniversity, Beijing, China临床科室泌尿外科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[10]Department of Urology, Beijing Hospital of theMinistry of Health, Beijing, China[11]Department of Urology, Shanghai FirstPeople’s Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China[12]Department of Urinary Surgery, the First Affiliated Hospital of WenzhouMedical College, Wenzhou, China[13]Department of Urology, China-JapanUnion Hospital, Jilin University, Changchun, China[14]Departmentof Urology,West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[15]Department of Urinary Surgery, Institute of Surgery Research, DapingHospital, Third Military Medical University, Chongqing, China[16]Departmentof Urology, Shougang Hospital of Peking University, Beijing, China[17]Department of Urology, Huadong Hospital, Fudan University, Shanghai,China[18]Department of Urology, Guangdong Provincial Hospital of ChineseMedicine, Guangzhou University of Chinese Medicine, Guangzhou, China[19]Department of Urology, Second Affiliated Hospital of Wenzhou MedicalCollege, Wenzhou, China[20]Department of Urology, Tianjin First CentralHospital, Tianjin, China[21]Department of Urology, Changhai Hospital, SecondMilitary Medical University, 168 Changhai Road, Shanghai 200433, China
Background: Although triptorelin is increasingly used in China for biochemical castration, its effects on primary prostate cancer symptoms remain unclear. This study aimed to assess the prevalence of lower urinary tract symptoms (LUTS) in Chinese prostate cancer patients and the effectiveness of triptorelin on LUTS. Methods: In this 48-week multicenter, non-interventional, prospective study, we enrolled patients with locally advanced or metastatic prostate cancer. Patients received triptorelin (15 mg) intramuscularly at baseline and at weeks 12, 24, and 36 with symptom assessment using the International Prostate Symptoms Score (IPSS). The primary endpoints were the prevalence of LUTS at baseline per IPSS categories and the percentage of patients with moderate to severe LUTS (IPSS > 7) at baseline, having at least a 3-point reduction of IPSS score at week 48. Results: A total of 398 patients were included; 211 (53.0%) and 160 (40.2%) among them had severe and moderate LUTS, respectively. Of the patients with IPSS scores available at baseline and at week 48 (n = 213), 81.2% achieved a reduction in IPSS of at least 3 points. Of the patients with moderate to severe LUTS at baseline and IPSS scores available at baseline and at week 48 (n = 194), 86.6% achieved a total IPSS reduction of at least 3 points. Conclusions: The vast majority of Chinese patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin as part of their standard treatment have severe or moderate LUTS. Triptorelin therapy resulted in sustained improvement of LUTS in these patients.
第一作者机构：[1]Department of Urology, Third Xiangya Hospital, Central South University,Changsha, Hunan, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
He Le-Ye,Zhang Ming,Chen Zhi-Wen,et al.Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study[J].BMC UROLOGY.2018,18:doi:10.1186/s12894-018-0337-4.
APA：
He, Le-Ye,Zhang, Ming,Chen, Zhi-Wen,Yuan, Jian-Lin,Ye, Ding-Wei...&Gao, Xu.(2018).Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study.BMC UROLOGY,18,
MLA：
He, Le-Ye,et al."Triptorelin relieves lower urinary tract symptoms in Chinese advanced prostate cancer patients: a multicenter, non-interventional, prospective study".BMC UROLOGY 18.(2018)
